Paradigm Asset Management’s Kite Pharma, Inc. KITE Stock Holding History

Paradigm Asset Management’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,700	Closed	-$78K	–	859
2016 Q1	$78K	Hold	1,700	–	–	0.01%	505
2015 Q4	$105K	Buy	+1,700	New	+$120K	0.02%	484

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Paradigm Asset Management's KITE Position: Q2 2016 in Review

Paradigm Asset Management sold out of Kite Pharma, Inc. (KITE) in Q2 2016, closing a stake of 1,700 shares — an estimated $78K sold.

Paradigm Asset Management first reported a position in KITE in Q4 2015 and held it in 2 quarters. The position peaked at $105K in Q4 2015. 173 funds tracked by Wall St. Rank hold KITE as of Q2 2016.

Paradigm Asset Management reported no remaining Kite Pharma, Inc. position as of Q2 2016 after selling out during the quarter.
Paradigm Asset Management sold 1,700 Kite Pharma, Inc. shares in Q2 2016, an estimated $78K.
Paradigm Asset Management first reported a position in Kite Pharma, Inc. in Q4 2015 and held it in 2 quarters.
Paradigm Asset Management's Kite Pharma, Inc. position peaked at $105K in Q4 2015.
173 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2016.

Based on Paradigm Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.